Multiplex CAR T Cell Targeting to Limit Tumor Antigen Escape
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CAR T cell therapies have limited efficacy against solid tumors, including brain cancers like glioblastoma and pediatric gliomas, and there is a need for more controllable and effective therapies for hematologic cancers such as multiple myeloma and lymphomas, as existing treatments face challenges with redundancy, intratumoral heterogeneity, and delivery issues.
Innovation Solution
A bifunctional compound comprising a synthetic antigen covalently linked to a targeting moiety that binds to multiple tumor-associated antigens, allowing for simultaneous targeting of multiple tumor antigens with CAR T cells, reducing antigen escape and toxicities by distributing antigen throughout the body, and enabling sequential or simultaneous administration of subpopulations to enhance therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CAR T cells target a single tumor antigen, then the therapy is simple to implement, but the efficacy is limited due to antigen escape and intratumoral heterogeneity
Solution Approach 1:
The patent applies multi-functionality by engineering CAR T cells to simultaneously target multiple tumor-associated antigens (such as CD19, CD22, and BCMA) through co-expression of multiple CAR constructs. This allows a single cell type to perform multiple targeting functions, overcoming antigen escape mechanisms while maintaining manageable system complexity through standardized CAR design modules
2Reliability
If CAR T cells are engineered to target multiple antigens simultaneously, then antigen escape is reduced, but the manufacturing complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the multi-antigen targeting capability into separate, modular CAR constructs that can be independently designed and validated. Each CAR targets a specific antigen (e.g., CD19 CAR, CD22 CAR, BCMA CAR), allowing standardized manufacturing protocols to be applied to each module separately before combination, thereby reducing overall manufacturing complexity
3Duration of action of moving object
If conventional treatments are used for glioblastoma, then the treatment protocol is established and simple, but the median survival is only 15 months with no salvage therapy
Solution Approach 1:
The patent applies parameter changes by fundamentally altering the therapeutic approach from conventional chemotherapy/radiation to genetically engineered cellular therapy. This changes key parameters including mechanism of action (direct cytotoxicity vs. indirect damage), delivery method (systemic administration vs. blood-brain barrier penetration), and durability (durable immune response vs. transient effect), thereby extending survival beyond the 15-month median while providing versatility through multiple targetable antigens
Data Source
AI summary
Disclosed are compositions and methods for treating cancers characterized by the presence of solid tumors, which simultaneously target a plurality of targets on cancer cells using single CAR T construct.